

BMJ Case Reports

Full clinical cases submission template

<p>TITLE OF CASE <i>Do not include "a case report"</i></p> <p>Invasive aspergillosis complicating treatment with Tyrosine Kinase Inhibitors</p>
<p>SUMMARY <i>Up to 150 words summarising the case presentation and outcome (this will be freely available online)</i></p> <p>We describe three cases of pulmonary aspergillosis (PA) in three patients without traditional risk factors for invasive aspergillosis infection, such as prolonged neutropenia or high dose systemic corticosteroid therapy. All three patients developed PA whilst taking tyrosine kinase inhibitors (TKI) and sustained greater clinical improvement once TKI were withdrawn. Our case series supports the theory TKI treatment can increase susceptibility to PA without causing neutropenia. Recognition that TKI treatment may predispose to invasive aspergillosis will allow for rapid recognition of patients of affected patients and more effective management of future cases.</p>
<p>BACKGROUND <i>Why you think this case is important – why did you write it up?</i></p> <p>The mitogen-activated protein kinase (MAPK) signalling pathway is involved in the pathophysiology of numerous cancers, including melanoma, leukaemia, pancreatic, colon, lung, biliary tract, salivary gland and thyroid carcinoma.[1,2] As a consequence, tyrosine kinase inhibitors that lead to MAPK pathway inhibition (MAPKi) are increasingly used in the treatment of malignant disease. Treatment with TKI causes a degree of immunosuppression and has been associated with the development of various infections including gastroenteritis, upper respiratory tract infection, acute bronchitis, pneumonia, bursitis, cellulitis and pyelonephritis.[3-5] A randomised double-blind placebo-controlled study of a highly selective p38 MAPK inhibitor demonstrated increased risk of infection compared with placebo (11% vs 5%), particularly serious infections (4.8% vs 0%).[3]</p> <p>An important infection of severely immunocompromised patients is acute pulmonary aspergillosis (PA), which is most commonly associated with prolonged neutropenia or treatment with high dose systemic corticosteroids.[6,7] More indolent forms of pulmonary aspergillosis are associated with chronic lung disease and milder immunodeficiencies. Here we describe three cases of PA developing in patients receiving TKI treatment, an association that has only recently been reported with ibrutinib.[8-14]</p>
<p>CASE PRESENTATION <i>Presenting features, medical/social/family history</i></p> <p>Patient 1</p> <p>A 63-year-old female was commenced on ibrutinib 420mg OD for chronic B cell lymphocytic leukaemia (CLL). Previous chemotherapy treatment included 2 cycles of fludarabine, cyclophosphamide and rituximab (FCR) over 40 months prior, and 2 cycles of reduced intensity FCR 27 months prior, to starting ibrutinib. She had also received 4 months of Ofatumumab (monoclonal antibody to CD20) as part of a trial, which was stopped 4 months before commencing ibrutinib due to rising white cell count. She required one tapering course of systemic steroids for autoimmune haemolytic anaemia eight months prior to commencing ibrutinib. On day +10 of ibrutinib the patient presented with fever and cough productive of yellow sputum and was treated with seven days of co-amoxiclav and clarithromycin. She re-presented to hospital on day +15 of ibrutinib treatment with persistent fevers and rigors, and new mild left lower limb</p>

PLEASE DELETE THIS PAGE BEFORE SUBMITTING YOUR ARTICLE

pyramidal weakness. There were multiple new densities throughout both lungs on her chest x-ray. Neutrophil count was 1.39. Computed tomography (CT) scanning revealed multiple bilateral pulmonary (Fig. 1a), liver (Fig. 1b) and thyroid nodules, and space occupying lesions of the brain (Fig. 1c). CT guided biopsy of a right lower lobe lung nodule demonstrated fungal hyphae on histopathology and was culture positive for *Aspergillus fumigatus*. Additional liver and skin biopsies demonstrated the presence of *Aspergillus fumigatus* on histopathological analysis, with growth also on fungal culture. Thyroid nodule fine needle aspiration (FNA) showed necrosis and ghosts of fungal hyphae only. Brain biopsy was not performed. Despite treatment with triple antifungal therapy (ambisome, voriconazole and amphotericin B) and ibrutinib, the patient developed a new pustular lesion to the left arm. Skin punch biopsy demonstrated necrosis, fungal spores and hyphae suggestive of *Aspergillus* on histopathology, and fungal culture demonstrated *Aspergillus fumigatus*. There was also radiological progression on CT chest. Once ibrutinib therapy was stopped no new lesions developed either clinically or radiologically. The patient was discharged home with posaconazole and flucytosine but continued to clinically deteriorate due to aggressive CLL and died on day +267.

Patient 2

A 58-year-old female with chronic myeloid leukaemia was treated with a succession of TKI over eight years, initially with imatinib, followed by nilotinib, dasatinib and finally changing to bosutinib 500 mg OD due to intolerance of the previous TKI. She had not received any other chemotherapy agent or systemic corticosteroids and had no history of neutropenia. She presented on day +61 of bosutinib therapy with breathlessness and was treated with a course of amoxicillin with no clinical improvement. The patient re-presented to our hospital on day +89 with fever, cough and dyspnoea. Construction work was being conducted within her home during this time. Chest x-ray demonstrated bilateral patchy areas of consolidation. Neutrophil count was 7.37. CT scan demonstrated multiple bilateral pulmonary macronodules with surrounding halos characteristic of PA (Fig. 2a). Blood and sputum cultures were negative. Serum galactomannan was not performed. The patient was too hypoxic to have a bronchoscopy. She was commenced empirically on ambisome, imipenem and amikacin, and the bosutinib was stopped. She made steady clinical and radiological improvement, and the antibiotics were stopped after two weeks. After 12 days the ambisome was switched to oral voriconazole for two months. She made a full clinical recovery, and repeat CT scanning showed resolution of the macronodules with residual focal scarring (Fig. 2b). Although Patient 2 lacked microbiological evidence of *Aspergillus* infection, the CT changes and steady clinical and radiological improvement with anti-fungal treatment was highly suggestive of PA rather than other infective diagnoses.

Patient 3

A 72-year-old male underwent a gastrectomy for a gastrointestinal stromal tumour of the stomach and was subsequently commenced on imatinib 200 mg OD, increasing to 300 mg, then 400 mg after six months. After 12 months of imatinib treatment, routine interval CT imaging revealed a new small cavitating left apical lung lesion at the site of a previously stable solid nodule (Fig. 3a). Although the patient remained asymptomatic, subsequent imaging over the next twelve months showed slowly progressive changes with the development of a new cavitating left upper lobe lesion and patchy nodular infiltrates. The patient was never neutropenic. Bronchoscopy was performed and bronchoalveolar lavage fluid from the left upper lobe contained fungal hyphae when examined by microscopy, and was culture positive for *Aspergillus fumigatus* and *Aspergillus flavus*. Bacterial and mycobacterial cultures were negative. He was treated initially with voriconazole 200 mg BD, which was stopped due to rash. Although voriconazole may increase plasma levels of TKIs, the dose of imatinib did not have to be adjusted after the introduction of voriconazole, with the measured voriconazole levels being within target therapeutic range. Repeat CT scan demonstrated progressive changes and IV caspofungin was commenced for 40 days. After four months, CT imaging demonstrated further progression and the patient was commenced on itraconazole, which was stopped within 2-3 weeks as he developed tremor and a flu-like reaction. At this time imatinib was stopped, and subsequently there was radiological (Fig. 3b) and microbiological improvement, with

negative <i>Aspergillus</i> culture on bronchoalveolar lavage, despite the patient not receiving continuing antifungal treatment.
INVESTIGATIONS <i>If relevant</i>
DIFFERENTIAL DIAGNOSIS <i>If relevant</i>
TREATMENT <i>If relevant</i>
OUTCOME AND FOLLOW-UP
(Please note that investigations, treatment and outcomes have been included within each case above for clarity and ease of reading. This is particularly necessary for the cases where further investigations and treatments occurred and I would be concerned that to split the cases up into sections would result in circular and difficult to read manuscript. I hope that is acceptable.)
DISCUSSION <i>Include a very brief review of similar published cases</i>
<p>Here we describe three cases of PA which did not at the time of developing the infection have the conventional high-risk factors for this infection (eg neutropenia, high dose systemic corticosteroids),[6,7] but were taking TKI. Patient 1 had biopsy-proven disseminated PA. Patient 2's CT changes and steady clinical and radiological improvement with anti-fungal treatment was highly suggestive of PA rather than other infective diagnoses. Patient 3 had radiological and microbiological evidence of slowly progressive PA. Withdrawal of TKI treatment was associated with no further progression of disseminated aspergillosis for Patient 1, despite prior progression on antifungals. Withdrawal of TKI treatment and concurrent antifungal treatment was associated with clinical and radiological improvement in Patient 2. Patient 3 demonstrated radiological and microbiological improvement on withdrawal of TKI, despite suboptimal antifungal therapy due to drug intolerance. These cases suggest that despite not causing neutropenia, treatment with TKI does increase susceptibility to <i>Aspergillus</i> infection. Our case series also suggests withdrawal of TKI promotes clinical recovery and should be considered in patients with significant evidence of active <i>Aspergillus</i> infection. Azole sensitivity testing is not routinely performed at our hospital but would have been important if any of our cases had exhibited poor clinical response to single agent azole therapy.</p> <p>If IPA is suspected clinically, early diagnostic tests should include blood and sputum cultures, serum galactomannan and early CT chest. Bronchoscopy with bronchoalveolar lavage, or diagnostic tissue sampling with transbronchial or transthoracic biopsies, are useful to obtain microbiological diagnosis, but may not be suitable for all patients.</p> <p>A recent retrospective study shows increased incidence of invasive fungal infection in CLL patients taking ibrutinib.[8] Invasive aspergillosis accounted for 27/33 cases with a 11/27 demonstrating cerebral involvement. Another retrospective study has shown 37.2% of patients receiving ibrutinib for lymphoid cancer developed invasive fungal infection.[9] Multiple case reports also support an association of invasive aspergillosis with ibrutinib therapy,[10-14] with several case reports suggesting an association with cryptococcal infection.[14-20] Mucormycosis and <i>Pneumocystis jirovecii</i> with ibrutinib therapy have also been described.[21-23]</p>

There is considerably less data to support an association between either imatinib or bosutinib treatment with invasive fungal or *Aspergillus* infection. There is one report of early-onset mucormycosis in a patient with acute lymphoblastic leukaemia receiving imatinib alongside other immunosuppressive treatment,[24] and one case of *Candida krusei* and *Candida glabrata* pneumonia in a patient receiving imatinib only for chronic myeloid leukaemia.[25]

Recently, Herbst *et al* described a macrophage cell signaling pathway (TLR9-BTK-calcineurin-NFAT) that requires activation of Bruton's Tyrosine Kinase (BTK). This macrophage signalling pathway is critically important for rapid recruitment of neutrophils. A deficient early chemokine response leads to impaired neutrophil recruitment and reduced immunity against *Aspergillus* infection in zebrafish.[26] BTK's importance in innate immune system's response to fungal infection has also recently been demonstrated in murine models,[27] and has also been implicated in immune responses to *Candida* infection.[28] Ibrutinib, imatinib and bosutinib inhibit BTK, and these findings provide a potential mechanism by which TKI could predispose to PA in patients with a normal circulating neutrophil count.

Recognition that TKI, may predispose to invasive aspergillosis, and potentially other fungal infections, such as cryptococcosis and mucor,[14-21] will allow rapid recognition of affected patients and more effective management of future cases.

LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points – this is a required field

- Long-term steroids and prolonged neutropenia are considered typical risk factors for developing invasive aspergillosis infection
- Treatment with mitogen-activated protein kinase inhibitors may also be a risk factor for invasive aspergillosis
- A high index of suspicion for patients with fever, cough and imaging possibly consistent with invasive aspergillosis in patients taking TKI is recommended, with early commencement of anti-fungal therapy
- Stopping TKI treatment whilst treating for invasive aspergillosis may aid recovery
- A potential mechanism for TKI predisposing to invasive aspergillosis with a normal circulating neutrophil is through inhibition of macrophage cell signalling pathways that are critically important for rapid recruitment of neutrophils against *Aspergillus*

REFERENCES Vancouver style (Was the patient involved in a clinical trial? Please reference related articles)

1. Xing L. Clinical candidates of small molecule p38 MAPK inhibitors for inflammatory diseases. MAP Kinase. 2016 Jan 19;4(1).
2. Martin-Liberal J, Larkin J. New RAF kinase inhibitors in cancer therapy. Expert Opin Pharmacother. 2014 Jun 28;15(9):1235–45.
3. Sweeney SE, Firestein GS. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis. 2006 Nov 1;65 Suppl 3(suppl_3):iii83-8.
4. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232–41.
5. Reinwald M, Silva JT, Mueller NJ, Fortún J, Garzoni C, de Fijter JW, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. Elsevier; 2018 Jun 1;24 Suppl 2:S53–70.
6. Herbrecht R, Bories P, Moulin J-C, Ledoux M-P, Letscher-Bru V. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci. 2012 Dec;1272(1):23–30.

7. Chen J, Yang Q, Huang J, Li L. Risk Factors for Invasive Pulmonary Aspergillosis and Hospital Mortality in Acute-On-Chronic Liver Failure Patients: A Retrospective-Cohort Study. *Int J Med Sci.* 2013;10(12):1625–31.
8. Ghez D, Calleja A, Protin C, Baron M, Ledoux M-P, Damaj G, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. *Blood.* 2018 Feb 1;blood-2017-11-818286.
9. Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM, et al. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. *Clin Infect Dis.* 2018 Aug 16;67(5):687–92.
10. Arthurs B, Wunderle K, Hsu M, Kim S. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. *Respir Med case reports.* 2017;21:27–9.
11. Faisal MS, Shaikh H, Khattab A, Albrethsen M, Fazal S. Cerebral aspergillosis in a patient on ibrutinib therapy—A predisposition not to overlook. *J Oncol Pharm Pract.* 2018 Jul 25.
12. Kreiniz N, Bejar J, Polliack A, Tadmor T. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma. *Hematol Oncol.* 2018 Feb;36(1):349–54.
13. Peri AM, Bisi L, Cappelletti A, Colella E, Verga L, Borella C, et al. Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report. *Clin Microbiol Infect.* 2018 Jul;24(7):785–6.
14. Baron M, Zini JM, Challan Belval T, Vignon M, Denis B, Alanio A, et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. *Leuk Lymphoma.* 2017 Dec 2;58(12):2981–2.
15. Okamoto K, Proia LA, Demarais PL. Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib. *Case Rep Infect Dis.* 2016;2016:1–3.
16. Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib. *Open Forum Infect Dis.* 2016 Dec 26;4(1):ofw261.
17. Sudhakaran S, Bashoura L, Stewart J, Balachandran DD, Faiz SA. Pulmonary *Cryptococcus* Presenting as a Solitary Pulmonary Nodule. *Am J Respir Crit Care Med.* 2017 Nov ;196(9):1217–8.
19. Swan CD, Gottlieb T. *Cryptococcus neoformans* empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature. *BMJ Case Rep.* 2018 Jul 18;2018:bcr-2018-224786.
20. Stankowicz M, Banaszynski M, Crawford R. Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia. *J Oncol Pharm Pract.* 2018 Jan 17;107815521775207.
21. Stein MK, Karri S, Reynolds J, Owsley J, Wise A, Martin MG, et al. Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. *World J Oncol.* 2018 Apr;9(2):62–5.
22. Lee R, Nayernama A, Jones SC, Wroblewski T, Waldron PE. Ibrutinib-associated *Pneumocystis jirovecii* pneumonia. *Am J Hematol.* Wiley-Blackwell; 2017 Nov 1;92(11):E646–8.
23. Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical *Pneumocystis jirovecii* pneumonia in previously untreated patients with CLL on single-agent ibrutinib. *Blood.* 2016 Oct 13;128(15):1940–3.
24. Crisan AM, Ghiaur A, Stancioaca MC, Bardas A, Ghita C, Manea CM, et al. Mucormycosis during Imatinib treatment: case report. *J Med Life.* 8(3):365–70.
25. Speletas M, Vyzantiadis T-A, Kalala F, Plastiras D, Kokoviadou K, Antoniadis A, et al. Pneumonia caused by *Candida krusei* and *Candida glabrata* in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment. *Med Mycol.* 2008 Jan;46(3):259–63.
26. Herbst S, Shah A, Mazon Moya M, Marzola V, Jensen B, Reed A, et al. Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to *Aspergillus fumigatus*. *EMBO Mol Med.* 2015 Mar;7(3):240–58.
27. Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. *Cancer Cell.* 2017 Jun 12;31(6):833–843.e5.
28. Strijbis K, Tafesse FG, Fairn GD, Witte MD, Dougan SK, Watson N, et al. Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of *Candida albicans* in Macrophages. May RC, editor. *PLoS Pathog.* 2013 Jun 27;9(6):e1003446.

FIGURE/VIDEO CAPTIONS *figures should NOT be embedded in this document*

Figure 1a: Bilateral nodular consolidation on CT chest
Figure 1b: Liver nodule on CT imaging of the upper abdomen
Figure 1c: Space-occupying lesions demonstrated on MRI brain
Figure 2a: Bilateral macronodules with surrounding halos on CT chest
Figure 2b: Resolution of macronodules with residual focal scarring on repeat CT chest
Figure 3a: Left upper lobe cavitating lesion on CT chest
Figure 3b: Filling in of left upper lobe cavity on repeat CT chest

PATIENT'S PERSPECTIVE *Optional but strongly encouraged – this has to be written by the patient or next of kin*

Copyright Statement

I, Jeremy Brown, The Corresponding Author, has the right to assign on behalf of all authors and does assign on behalf of all authors, a full assignment of all intellectual property rights for all content within the submitted case report (other than as agreed with the BMJ Publishing Group Ltd) ("BMJ") in any media known now or created in the future, and permits this case report (if accepted) to be published on BMJ Case Reports and to be fully exploited within the remit of the assignment as set out in the assignment which has been read. <http://casereports.bmj.com/site/misc/copyright.pdf>.

Date: 30/05/2018

PLEASE SAVE YOUR TEMPLATE WITH THE FOLLOWING FORMAT:

Corresponding author's last name and date of submission, eg,

Smith_September_2017.doc

License Statement

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Case Reports and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.